FDA-approved
Sexual & reproductive
Triptorelin
Evidence
FDA approved
Class
GnRH agonist
KEY TAKEAWAY
Triptorelin is a ten-amino-acid synthetic GnRH agonist. It is sold as Trelstar and Triptodur. The FDA approved triptorelin (Trelstar) in 2000 for advanced prostate cancer and (Triptodur) in 2017 for central precocious puberty.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH agonist
Approved for
Advanced prostate cancer and central precocious puberty
Key fact
The FDA approved triptorelin (Trelstar) in 2000 for advanced prostate cancer and (Triptodur) in 2017 for central precocious puberty.
Route
Intramuscular injection every 1 to 6 months
Evidence strength
FDA approved
Triptorelin is a ten-amino-acid synthetic GnRH agonist. It is sold as Trelstar and Triptodur.
It first stimulates and then desensitizes GnRH receptors, which lowers testosterone and estrogen.
The FDA approved triptorelin (Trelstar) in 2000 for advanced prostate cancer and (Triptodur) in 2017 for central precocious puberty.
Advanced prostate cancer and central precocious puberty.
Hot flashes, injection-site pain, bone density loss and sexual side effects are common.
U.S. FDA prescribing information for Triptorelin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.